Skip to main content

Umbrella menu

  • SfN.org
  • eNeuro
  • The Journal of Neuroscience
  • Neuronline
  • BrainFacts.org

Main menu

  • HOME
  • CONTENT
    • Early Release
    • Featured
    • Current Issue
    • Issue Archive
    • Collections
  • ALERTS
  • FOR AUTHORS
    • Preparing a Manuscript
    • Submission Guidelines
    • Fees
    • Journal Club
    • eLetters
    • Submit
  • EDITORIAL BOARD
  • ABOUT
    • Overview
    • Advertise
    • For the Media
    • Rights and Permissions
    • Privacy Policy
    • Feedback
  • SUBSCRIBE
  • SfN.org
  • eNeuro
  • The Journal of Neuroscience
  • Neuronline
  • BrainFacts.org

User menu

  • Log in
  • Subscribe
  • My alerts

Search

  • Advanced search
Journal of Neuroscience
  • Log in
  • Subscribe
  • My alerts
Journal of Neuroscience

Advanced Search

Submit a Manuscript
  • HOME
  • CONTENT
    • Early Release
    • Featured
    • Current Issue
    • Issue Archive
    • Collections
  • ALERTS
  • FOR AUTHORS
    • Preparing a Manuscript
    • Submission Guidelines
    • Fees
    • Journal Club
    • eLetters
    • Submit
  • EDITORIAL BOARD
  • ABOUT
    • Overview
    • Advertise
    • For the Media
    • Rights and Permissions
    • Privacy Policy
    • Feedback
  • SUBSCRIBE
PreviousNext
SYMPOSIA AND MINI-SYMPOSIA

Neurobiological Mechanisms of the Placebo Effect

Fabrizio Benedetti, Helen S. Mayberg, Tor D. Wager, Christian S. Stohler and Jon-Kar Zubieta
Journal of Neuroscience 9 November 2005, 25 (45) 10390-10402; DOI: https://doi.org/10.1523/JNEUROSCI.3458-05.2005
Fabrizio Benedetti
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Helen S. Mayberg
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tor D. Wager
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christian S. Stohler
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jon-Kar Zubieta
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Article Figures & Data

Figures

  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Events that might take place in the brain after placebo administration. Placebo administration (psychosocial context) might reduce pain through opioid and/or non-opioid mechanisms via expectations and/or conditioning mechanisms. The respiratory centers may also be inhibited by endogenous opioids. The β-adrenergic sympathetic system of the heart may also be inhibited during placebo analgesia, although the mechanism is not known (reduction of the pain itself and/or direct action of endogenous opioids). CCK antagonizes the effects of endogenous opioids, thereby reducing the placebo response. Placebos can also act on 5-HT-dependent hormone secretion, on both the pituitary and adrenal glands, thereby mimicking the effect of the analgesic drug sumatriptan. From Colloca and Benedetti (2005).

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    Correlation between subjective report (italics), arm rigidity (black circles), and subthalamic nucleus neuronal frequency discharge (bars) in two representative Parkinson's disease patients. The black arrow on the abscissa indicates placebo administration. Note the subjective sensation of well-being, along with arm rigidity decrease and neuronal firing rate reduction, in the placebo responder (a) but not in the nonresponder (b). Modified from Benedetti et al. (2004).

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    Effects of placebo on the activation of μ-opioid receptor-mediated neurotransmission. After correction for multiple comparisons, significant effects of placebo on the activation of the μ-opioid system (n = 14) were detected in the left DLPFC (x, y, z peak coordinates, -36, 13, 39; cluster size, 1403 mm3; z score, 4.27; p < 0.0001), rostral anterior cingulate (RACing; x, y, z, 14, 49, 13; cluster size, 3193 mm3, z score, 4.18; p < 0.0001), left nucleus accumbens (NAcc; x, y, z, -7, 11, -11; cluster size, 1332 mm3; z score, 4.83; p < 0.0001), and right anterior insula (Ins; x, y, z, 41, 10, -17; cluster size, 844 mm3; z score, 4.15; p < 0.05). The posterior right insula achieved subthreshold levels of significance (44, -15, 4; cluster size, 732 mm3; z score, 3.81; p < 0.0001 uncorrected for multiple comparisons). z scores of statistical significance are represented by the pseudocolor scale on the right side of the image and are superimposed over an anatomically standardized MRI image in coronal views. The left side of the axial and coronal images corresponds to the right side of the body (contralateral to pain) (radiological convention).

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    Individual data points for the magnitude of regional μ-opioid system activation in response to the placebo intervention. Individual data points for the change in the binding potential measure (μ-opioid receptor availability in vivo; Bmax/Kd) from the pain condition to the pain plus placebo condition. A threshold of 10% increase in the activation of this neurotransmitter system, evidenced as a reduction in the binding potential measure during the placebo condition, was used to identify individuals that responded with a robust placebo effect on the activation of this system in each of the regions (dotted line). Colors depict the data for each individual subject to highlight regional differences in the individual placebo response. ACing_Rostral, Rostral (pregenual) region of the anterior cingulate; DLPFC_Left, left dorsolateral prefrontal cortex; Insula_Right, right insular cortex; N.Acc._Left, left nucleus accumbens.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    Placebo-induced increases (placebo-controlled) in anticipation of pain (top left and slices at right) and during pain experience (bottom left) (from Wager et al., 2004). The threshold for display is set at p < 0.005, with the additional constraint of replication of effects within 10 mm across experiments 1 and 2. For space reasons, selected activations are shown.

  • Figure 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6.

    Changes in regional glucose metabolism (FDG PET) in fluoxetine (top), placebo (middle), and cognitive (bottom) therapy responders measured before and after a standard course of each respective treatment. Axial (left), sagittal (middle), and coronal (right) views; increases are in red, and decreases are in blue. The fluoxetine and placebo group were studied as part of the same double-blind controlled experiment. A common pattern of cortical increases and limbic-paralimbic decreases is seen in both groups, with the active fluoxetine group showing additional changes in the brainstem, hippocampus, insula, and caudate. In contrast, CBT response is associated with a distinctly different pattern: dorsolateral and medial frontal decreases and hippocampal increases. These findings suggest that the placebo changes are unlikely attributable to passive psychotherapy effects but rather specific effects attributable to the effects of expectation and conditioning facilitated by the psychosocial context of the trial. Slice location is in millimeters relative to anterior commissure. Numbers are Brodmann designations. ACing, Subgenual cingulate BA 25; PCing, posterior cingulate; P, pons; Hc, hippocampus; PFC, prefrontal cortex BA 9; Ins, anterior insula; Cau, caudate; OFC, orbital frontal cortex BA 11; MFC, medial frontal cortex BA 9.

  • Figure 7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 7.

    Time course of regional metabolic changes in drug nonresponders (left), drug responders (middle), and placebo responders (right). Ventral striatal and orbital frontal increases are seen uniquely at 1 week (Fig. 8, top panel; middle and right images) of both active and sham treatment in those patients that go on to show clinical response at 6 weeks. Such changes are not seen in patients who failed to respond (left image) and are no longer present in either group of responders once clinical remission has been achieved (6 week time point; bottom). In contrast, response-specific changes in prefrontal cortex and subgenual cingulate are seen only at 6 weeks (bottom) and not at the 1 week time point. VST, Ventral striatum; OFC, orbital frontal cortex BA 11; MFC, medial frontal cortex; ACing25, subgenual cingulate BA 25; PFC, prefrontal cortex BA 9; Ins, anterior insula; ACing24, anterior cingulate BA 24.

  • Figure 8.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 8.

    Regions of the frontal lobes showing increased activity in recent studies of self-regulation. Increases are shown for delivery of opiate analgesics compared with resting nondrug control states (blue letters), downregulation of aversive emotional experience (green) through emotional reappraisal, and placebo effects on pain or emotional processing (red). Some peaks reflect regions for which increases in activity are correlated with reductions in negative emotional experience or pain. One exception is the study by Bishop et al. (2004) (B), in which frontal activation was correlated with reduced state anxiety. Peak locations from the same study within 12 mm were averaged together for clarity of presentation.

Back to top

In this issue

The Journal of Neuroscience: 25 (45)
Journal of Neuroscience
Vol. 25, Issue 45
9 Nov 2005
  • Table of Contents
  • About the Cover
  • Index by author
Email

Thank you for sharing this Journal of Neuroscience article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Neurobiological Mechanisms of the Placebo Effect
(Your Name) has forwarded a page to you from Journal of Neuroscience
(Your Name) thought you would be interested in this article in Journal of Neuroscience.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
View Full Page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Neurobiological Mechanisms of the Placebo Effect
Fabrizio Benedetti, Helen S. Mayberg, Tor D. Wager, Christian S. Stohler, Jon-Kar Zubieta
Journal of Neuroscience 9 November 2005, 25 (45) 10390-10402; DOI: 10.1523/JNEUROSCI.3458-05.2005

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Request Permissions
Share
Neurobiological Mechanisms of the Placebo Effect
Fabrizio Benedetti, Helen S. Mayberg, Tor D. Wager, Christian S. Stohler, Jon-Kar Zubieta
Journal of Neuroscience 9 November 2005, 25 (45) 10390-10402; DOI: 10.1523/JNEUROSCI.3458-05.2005
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • The pharmacological approach
    • The placebo effect in motor control: studies in Parkinson's disease
    • Endogenous opioid mechanisms in placebo analgesia: neuroimaging studies
    • Functional neuroanatomy of placebo analgesia
    • Neural responses to placebo in clinical trials of antidepressants
    • Relationship of placebo effects to other self-regulatory processes
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Responses to this article

Respond to this article

Jump to comment:

No eLetters have been published for this article.

Related Articles

Cited By...

More in this TOC Section

  • The β-Secretase Enzyme BACE in Health and Alzheimer's Disease: Regulation, Cell Biology, Function, and Therapeutic Potential
  • Nutrition, Brain Aging, and Neurodegeneration
  • Functional Properties of Synaptic Transmission in Primary Sense Organs
Show more Symposia and Mini-Symposia
  • Home
  • Alerts
  • Visit Society for Neuroscience on Facebook
  • Follow Society for Neuroscience on Twitter
  • Follow Society for Neuroscience on LinkedIn
  • Visit Society for Neuroscience on Youtube
  • Follow our RSS feeds

Content

  • Early Release
  • Current Issue
  • Issue Archive
  • Collections

Information

  • For Authors
  • For Advertisers
  • For the Media
  • For Subscribers

About

  • About the Journal
  • Editorial Board
  • Privacy Policy
  • Contact
  • Feedback
(JNeurosci logo)
(SfN logo)

Copyright © 2021 by the Society for Neuroscience.
JNeurosci Online ISSN: 1529-2401

The ideas and opinions expressed in JNeurosci do not necessarily reflect those of SfN or the JNeurosci Editorial Board. Publication of an advertisement or other product mention in JNeurosci should not be construed as an endorsement of the manufacturer’s claims. SfN does not assume any responsibility for any injury and/or damage to persons or property arising from or related to any use of any material contained in JNeurosci.